Evidence map›Paper›PMID 37226685›Full record

ArticleEMBO molecular medicine2023

FAM3C/ILEI protein is elevated in psoriatic lesions and triggers psoriasiform hyperproliferation in mice.

Barizah Malik, Iva Vokic, Thomas Mohr, Marle Poppelaars, Martin Holcmann, Philipp Novoszel, Gerald Timelthaler, Thomas Lendl, Dana Krauss, Ulrich Elling and 5 more

Open access · goldAbstract read
In one paragraph

Article in EMBO molecular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Barizah MalikCenter for Cancer Research, Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria.ORCID 0000-0001-7887-6545
Iva VokicCenter for Cancer Research, Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria.
Thomas MohrCenter for Cancer Research, Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria.
Marle PoppelaarsCenter for Cancer Research, Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria.ORCID 0000-0003-4648-7283
Martin HolcmannCenter for Cancer Research, Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria.ORCID 0000-0003-3362-1359
Philipp NovoszelCenter for Cancer Research, Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria.
Gerald TimelthalerCenter for Cancer Research, Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria.
Thomas LendlResearch Institute of Molecular Pathology, Vienna, Austria.
Dana KraussCenter for Cancer Research, Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria.ORCID 0000-0002-7310-4340
Ulrich EllingInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.
Michael MildnerDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-6892-925X
Josef M PenningerInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.ORCID 0000-0002-8194-3777
Peter PetzelbauerDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-7080-5259
Maria SibiliaCenter for Cancer Research, Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria.ORCID 0000-0001-6129-5613
Agnes CsiszarCenter for Cancer Research, Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria.ORCID 0000-0001-7911-3427
Comprehensive Cancer Center Vienna · ATInstitute of Molecular Biotechnology · ATMedical University of Vienna · ATResearch Institute of Molecular Pathology · ATUniversity of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FAM3C/ILEI is an important cytokine for tumor progression and metastasis. However, its involvement in inflammation remains elusive. Here, we show that ILEI protein is highly expressed in psoriatic lesions. Inducible keratinocyte-specific ILEI overexpression in mice (K5-ILEI

Indexed as

PsoriasisUrokinase-Type Plasminogen ActivatorAnimalsCytokinesKeratinocytesMiceSignal TransductionCytokinesUrokinase-Type Plasminogen ActivatorILEI/FAM3Cinflammationkeratinocyte differentiationpsoriasisuPA/PLAU

Identifiers

PMID37226685
PMCPMC10331587
OpenAlexW4378172285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.